XL National Meeting of the
Spanish Society of Pharmacology

Toledo, September 6 to 8 - 2023


Local Organizing Committee:

President: Valentín Ceña
Secretary: Inmaculada Posadas

Vanesa Guijarro
Mar Morales
María Dolores Pérez-Carrión
Krzysztof Stzandera
Irene Rodríguez Clemente
Filipe Olim
Ángel Buendía

Scientific Committee:

President: Julio Cortijo
Secretary: Mercè Pallàs

José Manuel Brea
Ricardo Caballero
Eva Delpón
Andrés Fernández
Rosario Jiménez
Mabel Loza
Antonio Rodríguez Artalejo
María Jesús Sanz
Maria Teresa Tejerina
Francisco Zaragozá


Virgil Percec

Virgil Percec got his Ph.D. in 1976 at the Institute of Macromolecular Chemistry in Iasi, Romania. In 1981, he joined the Department of Macromolecular Science of Case Western Reserve University in Cleveland, US in March 1982 as an Assistant Professor. He was promoted to Associate Professor in 1984 and to Professor in 1986. In 1993 he was awarded the Leonard Case Jr. Chair at Case Western Reserve University and in 1999 he was invited and moved to the University of Pennsylvania in Philadelphia as P. Roy Vagelos Chair and Professor of Chemistry.

He has received many awards including, among others, the Humboldt Award for Senior US Scientists (1997), the NSF Research Award for Creativity in Research (1990, 1995, 2000), Fellow of the American Association for the Advancement of Science (2004), the ACS Award in Polymer Chemistry (2004), the Staudinger Medal from ETH (2005), the International Award of the Society of Polymer Science from Japan (2007), the H.F. Mark Medal from the Austrian Institute for Science and Technology (2008), and the Humboldt Award for Senior US Scientists (2011).

Currently, he is on the Editorial and Advisory Boards of 22 International Journals, on the Scientific Advisory Boards of several Companies, National Laboratories and of the Australian Institute for Bioengineering & Nanoscience. He is a consultant to numerous US and International Companies and Governmental Offices. He was ranked by Thomson Reuters as one of the “World’s Most Influential Scientific Minds” for the years 2014, 2015, and 2016. He was selected in “Global Highly Cited Researchers” List by Clarivate Analytics for 2018. This list recognizes world-class researchers for their exceptional research performance based on multiple highly cited papers that rank in the top 1% by citations for field and year in Web of Science.

His research interest is at the interface between organic, supramolecular, macromolecular chemistries, liquid crystals, nanoscience and biology where he contributed over 820 refereed publications receiving over 50,000 citations, 80 patents, edited 19 books and presented over 1250 endowed, invited and plenary lectures. His h-index is 122.

Graeme Milligan

Graeme Milligan Ph.D., FRSE, FMEd Sci, FBPharmacolS. Graduated in Biochemistry at the University of Nottingham in 1982 and got his Ph.D. in 1982 at the same university. He is Gardiner Professor of Biochemistry, former Dean of Research and current Deputy Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow. He has received several awards including the ‘Poulsson’ Medal for Pharmacology from the Norwegian Society of Pharmacology and Toxicology (1998), the Ariens Medal from the Dutch Pharmacological Society (2006), and the JR Vane Medal for Pharmacology from the British Pharmacological Society (2016).

His main research group centres on the function, structure, and regulation of G protein-coupled receptors (GPCRs) and their interacting proteins. His experience also includes translating knowledge generated into selection of targets, screening, and identification of small molecule regulators of these proteins and progressing such ligands in drug development programmes. Prof. Milligan has published more than 600 peer-reviewed articles and his research has been cited more than 40,000 times. His h-index is 103. He was elected to the Fellowship of the Royal Society of Edinburgh in 1998 and to the Fellowship of the Academy of Medical Sciences in 2016.

Prof. Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for metabolic diseases including Type 2 Diabetes and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and of Keltic Pharma Therapeutics (2020) which is developing new treatments for malaria.

Michael Spedding

 Dr. Spedding got his Ph.D. in 1974 at the Department of Pharmacology, Sunderland Polytechnic University. He is among the 150 most cited researchers in France (2013-2020 by Clarivate, all disciplines). He has published more than 250 papers that have been cited more than 28,000 times with an H-index of 76. He has a very broad experience in drug development as Scientific Director of Servier for more than 20 years where he was responsible for the development from discovery to the end of phase II of three drugs (ranolazine, lifarizine, delequamine). He is member of the French Academy of Pharmacy, (2001) and Fellow of the British Pharmacological Society (2005).

He is Secretary General of the International Union of Pharmacology (IUPHAR) and Chairman of NC-IUPHAR Committee. He has a great interest in education in Pharmacology mainly directed to young pharmacologists at early stages of their scientific careers. He is deeply involved in the IUPHAR/BPS Guide to PHARMACOLOGY update and maintenance as well as to facilitate interaction among pharmacologists at the global level.